[go: up one dir, main page]

WO2009033811A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009033811A3
WO2009033811A3 PCT/EP2008/008155 EP2008008155W WO2009033811A3 WO 2009033811 A3 WO2009033811 A3 WO 2009033811A3 EP 2008008155 W EP2008008155 W EP 2008008155W WO 2009033811 A3 WO2009033811 A3 WO 2009033811A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
asn
muroctasin
compositions
phe
Prior art date
Application number
PCT/EP2008/008155
Other languages
English (en)
Other versions
WO2009033811A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Laboratories Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories Ag filed Critical Mondobiotech Laboratories Ag
Publication of WO2009033811A2 publication Critical patent/WO2009033811A2/fr
Publication of WO2009033811A3 publication Critical patent/WO2009033811A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pediatric Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Ac-muramyl-Ala-D-Glu(Lys(stearoyl)-OH)-NH2 et Leu-Pro-Asn-Tyr- Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008155 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique WO2009033811A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017753 2007-09-11
EP07017760.5 2007-09-11
EP07017760 2007-09-11
EP07017753.0 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033811A2 WO2009033811A2 (fr) 2009-03-19
WO2009033811A3 true WO2009033811A3 (fr) 2009-08-27

Family

ID=40452595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008155 WO2009033811A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009033811A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016713A2 (fr) * 1992-02-28 1993-09-02 Peptech (Uk) Limited Composes a usage medical

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016713A2 (fr) * 1992-02-28 1993-09-02 Peptech (Uk) Limited Composes a usage medical

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ARLETTE ADAM, EDGAR LEDERER: "Muramyl peptides: Immunomodulators, sleep factors, and vitamins", MEDICINAL RESEARCH REVIEWS, vol. 4, no. 2, 1984, pages 111 - 152, XP002526135 *
IBELGAUFTS H.: "Romurtide", HORST IBELGAUFTS' COPE: CYTOKINES & CELLS ONLINE PATHFINDER ENCYCLOPAEDIA, 27 January 2008 (2008-01-27), XP002526133, Retrieved from the Internet <URL:http://www.copewithcytokines.de/cope.cgi?key=romurtide> [retrieved on 20090430] *
KEVIN T. NASH AND DANNY R. WELCH: "The KISS1 metastasis suppressor: mechanistic insights and clinical utility", NATIONAL INSTITUTES OF HEALTH, vol. 11, 1 January 2006 (2006-01-01), pages 647 - 659, XP002519269 *
KOTANI MASATO ET AL: "The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 276, no. 37, 14 September 2001 (2001-09-14), pages 34631 - 34636, XP002262291, ISSN: 0021-9258 *
LEE J-H ET AL: "KiSS-1, a novel human malignant melanoma metastasis-suppressor gene", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 88, no. 23, 4 December 1996 (1996-12-04), pages 1731 - 1737, XP002954456, ISSN: 0027-8874 *
LEE J-H ET AL: "SUPPRESSION OF METASTASIS OF HUMAN BREAST CARCINOMA MDA-MB-435 CELLS AFTER TRANSFECTION WITH THE METASTASIS SUPPRESSOR GENE, KISS-1", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 57, no. 12, 15 June 1997 (1997-06-15), pages 2384 - 2387, XP001157362, ISSN: 0008-5472 *
MEAD E J ET AL: "Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, vol. 151, no. 8, 1 August 2007 (2007-08-01), pages 1143 - 1153, XP009113650, ISSN: 0007-1188, [retrieved on 20070521] *
OHTAKI T ET AL: "METASTASIS SUPPRESSOR GENE KISS-1 ENCODES PEPTIDE LIGAND OF A G-PROTEIN-COUPLED RECEPTOR", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 411, 31 May 2001 (2001-05-31), pages 613 - 617, XP002942231, ISSN: 0028-0836 *
UEDA H, YAMAZAKI M.: "Induction of tumor necrosis factor-alpha in solid tumor region by the orally administered synthetic muramyl dipeptide analogue, romurtide.", INT IMMUNOPHARMACOL, vol. 1, no. 1, 2001, pages 97 - 104, XP002526136 *
YANAGAWA H .ET AL.: "Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer", LUNG CANCER, vol. 27, 2000, pages 67 - 73, XP002526134 *
YUNG CHOON Y ET AL: "MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 12, no. 2, 1 January 1994 (1994-01-01), pages 175 - 180, XP023709892, ISSN: 0264-410X, [retrieved on 19940101] *

Also Published As

Publication number Publication date
WO2009033811A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043522A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043518A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2008075371A3 (fr) Analogues peptidiques de t-140 présentant une activité superagoniste par rapport à cxcr4 destinés à une immunomodulation
WO2009002947A3 (fr) Composés et peptides de liaison au récepteur de trail
WO2009059325A3 (fr) Compositions de peptide hpv multitype et procédés de traitement ou de prévention d&#39;une infection par papillomavirus humain
WO2009126688A3 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2008129422A8 (fr) Facteur viii recombinant démannosylé pour le traitement de patients atteint d&#39;une hémophilie a
WO2004064717A3 (fr) Copolymere 1 pour le traitement de maladies enteriques inflammatoires
WO2009033819A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2008113770A3 (fr) Peptides anti-androgènes et leurs utilisations dans le traitement du cancer
WO2009158238A3 (fr) Analogues de facteur de croissance de fibroblaste (fgf) et leurs utilisations
WO2009043525A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033813A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009046875A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2004110466A3 (fr) Pediocoques a biere produisant de la pediocine
WO2009033814A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033820A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033816A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033818A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2006095173A3 (fr) Utilisation d&#39;un compose
WO2009033811A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033809A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009046872A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043523A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802620

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802620

Country of ref document: EP

Kind code of ref document: A2